Recombinant
RabMAb

Anti-CDKN2A/p16INK4a antibody [EP435Y-129R] (ab81278)

Overview

  • Product name
    Anti-CDKN2A/p16INK4a antibody [EP435Y-129R]
    See all CDKN2A/p16INK4a primary antibodies
  • Description
    Rabbit monoclonal [EP435Y-129R] to CDKN2A/p16INK4a
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, ICC/IF, Flow Cytmore details
    Unsuitable for: IHC-P or IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant full length Human CDKN2A/p16INK4a tagged

  • Positive control
    • HeLa cells and 293 cell lysate
  • General notes

    A trial size is available to purchase for this antibody.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab81278 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/2000. Predicted molecular weight: 17 kDa.
ICC/IF 1/100 - 1/500.
Flow Cyt 1/50 - 1/100.

ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.

  • Application notes
    Is unsuitable for IHC-P or IP.
  • Target

    • Cellular localization
      Cytoplasmic and Nuclear
    • Database links
    • Form
      There are 4 isoforms produced by alternative splicing. Isoform 1 also known as: p16INK4a; Isoform 3 also known as: p12; Isoform 4 also known as: p14ARF; p19ARF; ARF.
    • Alternative names
      • CCM2 antibody
      • CDK4 inhibitor p16 INK4 antibody
      • CDK4I antibody
      • CDKN2 antibody
      • CDKN2A antibody
      • Cell cycle negative regulator beta antibody
      • CMM2 antibody
      • Cyclin dependent kinase 4 inhibitor A antibody
      • Cyclin dependent kinase inhibitor 2A (melanoma p16 inhibits CDK4) antibody
      • Cyclin Dependent Kinase Inhibitor 2A antibody
      • Cyclin dependent kinase inhibitor 2A isoform 4 antibody
      • Cyclin dependent kinase inhibitor 2A isoforms 1/2/3 antibody
      • Cyclin dependent kinase inhibitor p16 antibody
      • INK4 antibody
      • INK4A antibody
      • MLM antibody
      • MTS1 antibody
      • Multiple tumor suppressor 1 antibody
      • p14 antibody
      • p16 antibody
      • P16INK4 antibody
      • p16INK4a antibody
      • p19 antibody
      • p19Arf antibody
      • TP16 antibody
      see all

    Images

    • Immunofluorescent staining of HeLa cells using 1/100 ab81278
    • Overlay histogram showing HEK293 cells stained with ab81278 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab81278, 1/100 dilution) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-rabbit IgG (H+L) (ab96899) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was rabbit IgG (monoclonal) (1µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HEK293 cells fixed with 80% methanol (5 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.

    • All lanes : Anti-CDKN2A/p16INK4a antibody [EP435Y-129R] (ab81278) at 1/20000 dilution

      Lane 1 : HeLa cell
      lysate
      Lane 2 : 293 cell lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : HRP labelled goat anti rabbit at 1/2000 dilution

      Predicted band size: 17 kDa
      Observed band size: 17 kDa

    References

    This product has been referenced in:
    • Herling CD  et al. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun 9:727 (2018). Read more (PubMed: 29463802) »
    • Cretella D  et al. The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. J Exp Clin Cancer Res 37:72 (2018). Read more (PubMed: 29587820) »

    See all 11 Publications for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab81278.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up